SB 225002 |
| Katalog-Nr.GC16465 |
SB 225002, ein potenter, selektiver und nicht-peptidischer CXCR2-Antagonist, hemmt die 125I-IL-8-Bindung an CXCR2 mit einem IC50 von 22 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 182498-32-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SB 225002 is a potent and selective CXCR2 chemokine receptor antagonist that inhibits the binding of 125I-IL-8 (125I-labeled interleukin 8) and CXCR2 with an IC50 value of 22nM[1].
In HL60 cells, SB 225002 potently prevented IL-8 and GROα-induced neutrophil chemotaxis. In cells expressing predominantly CXCR2 (~80%) and to a lesser extent CXCR1 (~20%) receptors, SB 225002 produces concentration-dependent inhibition of IL-8 and GROα-mediated calcium mobilization, with IC50 values of 8 and 10nM, respectively[1]. GROβ enhances transcription of EGR-1, via the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway, which can be blocked by an antagonist of CXCR2 (SB 225002). 400nM of SB 225002 blocked CXCR2 signaling in WHCO1 cells and significantly reduced cell proliferation (40%-50%)[2].
SB 225002 (1.39-5.5μg/kg/min）selectively blocks IL-8-induced neutrophil marginalization in a neutrophil sequestration rabbit model[1]. SB 225002 (2mg/kg) did not affect ischemic brain damage in lipid-normal wild-type mice, but reversed the increased brain damage in hyperlipidemic ApoE-/- mice[3]. In a young rat model of lipopolysaccharide (LPS)-sensitized hypoxic-ischemic (HI) cerebral white matter injury, SB 225002 (1 or 3mg/kg) significantly attenuated microglia activation, blood-brain barrier (BBB) injury, and astrocyte hyperplasia in the white matter after LPS-sensitized HI[4].
References:
[1] White J R, Lee J M, Young P R, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration[J]. Journal of Biological Chemistry, 1998, 273(17): 10095-10098.
[2] Wang B, Hendricks D T, Wamunyokoli F, et al. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer[J]. Cancer research, 2006, 66(6): 3071-3077.
[3] Herz J, Sabellek P, Lane TE, Gunzer M, Hermann DM, Doeppner TR. Role of Neutrophils in Exacerbation of Brain Injury After Focal Cerebral Ischemia in Hyperlipidemic Mice. Stroke. 2015 Oct;46(10):2916-25.
[4] Wang LY, Tu YF, Lin YC, Huang CC. CXCL5 signaling is a shared pathway of neuroinflammation and blood-brain barrier injury contributing to white matter injury in the immature brain. J Neuroinflammation. 2016 Jan 6;13:6.
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *